🧾 What This Document Is

This is an 8-K filing, which companies use to announce major, timely news to investors. This specific one is an "Exhibit 99.1," which means it's a press release attached to the official filing. The news? Abeona has appointed a new, independent member to its Board of Directors.

🏢 What The Company Does

👉 In simple terms, Abeona Therapeutics is a biotech company that makes cutting-edge treatments called cell and gene therapies. These are for very serious, often genetic diseases. Their first approved product is ZEVASKYN®, a treatment for a severe skin condition called RDEB. They've moved from just researching cures to now actually selling and manufacturing one.

👥 The New Appointment

The company appointed Keith A. Goldan to its Board of Directors, effective April 1, 2026. He isn't just a regular board member; he will also be the Chairman of the Audit Committee. This is a crucial role overseeing the company's financial reporting and controls.

💼 Why Keith Goldan?

Mr. Goldan is being brought in for his deep financial expertise in the biotech world. Here’s his relevant experience:

• He’s currently the CFO of Syndax Pharmaceuticals, helping lead them through their first product approvals and launches.
• Previously, he was CFO of Optinose, where he helped build the commercial launch for their main product.
• He also served as CFO of Fibrocell, another cell and gene therapy company.
• His career includes multiple other CFO roles and experience raising capital, managing IPOs, and executing mergers.

🚀 Why It Matters

👉 Abeona is highlighting that it’s focused on "commercial momentum" and "growth." Hiring a board member with a strong background in scaling commercial operations and managing finances for publicly traded biotech companies signals they are serious about this next phase. As the Chairman said, his experience in "capital markets, corporate development, and operational scaling" is seen as invaluable for positioning the company for growth.

🔮 What This Signals

This move suggests Abeona is fortifying its leadership for a critical period. Moving from a research-focused company to a commercial one with a product on the market requires different financial and strategic skills. This appointment appears designed to strengthen that specific capability at the board level, ensuring strong oversight as they work to build sales and potentially expand their pipeline.

⚖️ Big Picture

👍 Strengths: The appointment adds experienced, relevant financial governance precisely when Abeona needs it to manage commercial growth. It shows proactive leadership. ⚠️ Risks: A single board change is not a magic bullet. Abeona still faces the core challenges of a commercial-stage biotech: successfully marketing ZEVASKYN, managing manufacturing costs, and advancing its pipeline. Execution remains key.

🧠 The Analogy

It’s like a promising sports team that just made it to the major leagues. They’re hiring a new general manager who has been there before—someone who knows how to handle the bigger contracts, the media, and the pressure of winning now, not just in the future.

🧩 Final Takeaway

Abeona Therapeutics is bolstering its Board of Directors with a seasoned financial expert from the biotech industry. This strategic hire underscores the company's shift into a commercial phase and its focus on strengthening financial and operational oversight as it works to grow its first product.